vedolizumab trough levels at week 6 and 14 correlate with clinical remission in inflammatory bowel disease patients

被引：0
|
作者：
Marino, M. [1 ]
Domenis, R. [2 ]
Biribin, L. [1 ]
Cifu, A. [2 ]
Navarria, L. [1 ]
Scardino, G. [1 ]
Fabris, M. [2 ]
机构：
[1] Azienda Sanit Univ Integrata Udine, Dept Gastroenterol, Udine, Italy
[2] Azienda Sanit Univ Integrata Udine, Ist Patol Clin, Udine, Italy
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P588
引用
收藏
页码：S492 / S492
页数：1
相关论文
共 50 条
  • [41] Serum levels of selected micronutrients in patients with inflammatory bowel disease in clinical remission
    Piatek-Guziewicz, Agnieszka
    Pasko, Pawel
    Wcislo, Kacper
    Dabek-Drobny, Agnieszka
    Przybylska-Felus, Magdalena
    Kaczmarczyk, Olga
    Zagrodzki, Pawel
    Mach, Tomasz
    Zwolinska-Wcislo, Malgorzata
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2021, 131 (7-8): : 701 - 708
  • [42] Efficacy and Safety of Vedolizumab in Patients with Inflammatory Bowel Disease in Association with Vedolizumab Drug Levels
    Huettemann, Eva
    Muzalyova, Anna
    Groehl, Katharina
    Nagl, Sandra
    Fleischmann, Carola
    Ebigbo, Alanna
    Classen, Johanna
    Wanzl, Julia
    Prinz, Friederike
    Mayr, Patrick
    Schnoy, Elisabeth
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (01)
  • [43] Effectiveness and safety of vedolizumab for the induction of remission in inflammatory bowel disease
    Chaparro, M.
    Sierra-Ausin, M.
    Mesonero, F.
    Maroto, N.
    Fernandez de Castro, C.
    Garcia-Sanchez, V.
    Lucendo, A. J.
    Busquets, D.
    Barreiro-de Acosta, M.
    Marin-Jimenez, I.
    Beltran, B.
    Ruiz Belmonte, L.
    Bermejo, F.
    Minguez, M.
    Pajares, R.
    Pineda, J. R.
    Sicilia, B.
    Martin-Rodriguez, D.
    Gutierrez, A.
    Rubio, S.
    Garcia Tercero, I.
    Piqueras, M.
    Ginard, D.
    Jucha, B.
    Munoz Villafranca, C.
    Martin-Arranz, M. D.
    Marti Romero, L.
    Fernandez Bonilla, E. M.
    Echarri, A.
    Forcelledo, J. F.
    Donday, M. G.
    Ramas, M.
    Gisbert, J. P.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S416 - S417
  • [44] Association between early vedolizumab trough levels and biochemical remission in patients with Crohn's disease
    Kim, Kyuwon
    Yoon, A-Ran
    Oh, Kyunghwan
    Hong, Hee Seung
    Lee, Jae Yong
    Hong, Seung Wook
    Park, Jin Hwa
    Hwang, Sung Wook
    Park, Sang Hyoung
    Yang, Dong-Hoon
    Byeon, Jeong-Sik
    Myung, Seung-Jae
    Yang, Suk-Kyun
    Ye, Byong Duk
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 276 - 277
  • [45] Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission
    Parisio, Laura
    Settanni, Carlo Romano
    Varca, Simone
    Laterza, Lucrezia
    Lopetuso, Loris Riccardo
    Napolitano, Daniele
    Schiavoni, Elisa
    Turchini, Laura
    Fanali, Caterina
    Alfieri, Norma
    Pizzoferrato, Marco
    Papa, Alfredo
    Pafundi, Pia Clara
    Armuzzi, Alessandro
    Gasbarrini, Antonio
    Pugliese, Daniela
    Scaldaferri, Franco
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2023, 32 (04) : 452 - 459
  • [46] Do antiTNF or Ustekinumab trough levels correlate with joint extraintestinal manifestations activity in Inflammatory bowel disease patients?
    Madero Velazquez, L.
    Zapater, P.
    Mira, C.
    Jovani, V.
    Andres, M.
    Aguas, M.
    Vicens, E.
    Barreiro-de Acosta, M.
    Perez-Pampin, E.
    Porto-Silva, M.
    Zabana, Y.
    Pujol, M.
    Herreros, B.
    Ojeda, A.
    Noguera, J. R.
    Rainieri, L.
    Bernal, L.
    Belen, O.
    Moreno, V.
    Cameo, J.
    Sempere, L.
    Mas-Serrano, P.
    Gutierrez Casbas, A.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I977 - I978
  • [47] Predictive value of infliximab trough levels in maintenance therapy for 5-year sustained clinical remission in patients with inflammatory bowel disease
    Jalali, Yashar
    Gojdicova, Anna
    Sturdik, Igor
    Toth, Jozef
    Koller, Tomas
    Huorka, Martin
    Jalali, Monika
    Payer, Juraj
    Hlavaty, Tibor
    BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2023, 124 (07): : 485 - 492
  • [48] Risk of relapse after vedolizumab withdrawal in Inflammatory Bowel Disease for patients in histological remission
    Blad, W.
    Whitley, L.
    Harrow, P.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 942 - 942
  • [49] Association between infliximab trough levels, clinical remission, mucosal healing and quality of life in patients with inflammatory bowel disease on maintenance therapy
    Parra, R. S.
    Feitosa, M. R.
    Feres, O.
    Rocha, J. J. R. D.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S292 - S292
  • [50] Higher Maintenance Adalimumab Trough Levels are Associated With Achievement of Advanced Remission Targets in Patients With Inflammatory Bowel Disease
    Ritter, Einat
    Hirsch, Ayal
    Isakov, Naomi F.
    Ron, Yulia
    Cohen, Nathaniel A.
    Maharshak, Nitsan
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2021, 55 (09) : 810 - 814
12345